Prosecution Insights
Last updated: April 19, 2026
Application No. 16/648,849

NOVEL COMPOSITION

Non-Final OA §103§112
Filed
Mar 19, 2020
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Glaxosmithkline Consumer Healthcare (Uk) Ip Limited
OA Round
8 (Non-Final)
48%
Grant Probability
Moderate
8-9
OA Rounds
4y 4m
To Grant
85%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
363 granted / 750 resolved
-11.6% vs TC avg
Strong +36% interview lift
Without
With
+36.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
78 currently pending
Career history
828
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
49.2%
+9.2% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 750 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments in the Request for Continued Examination, filed January 16, 2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims Claim Rejections - 35 USC § 112 (New Rejections) New Matter The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4 and 6-8 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims recite the ratio 1:4. However there appears to be no support for this ratio. Therefore 1:4 is considered “New Matter”. Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1-4 and 6-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites at least 0.3% betaine and at least 0.5% sodium lauryl sulfate. However these amounts do not fall within the ratio range. Therefore the claims are indefinite. Claim Rejections - 35 USC § 103 – Obviousness (New Rejection) Claims 1-4 and 6-8 are rejected under 35 U.S.C. 103 as being unpatentable over Xu et al. (US 2002/0031481) in view of Gorlin et al. (US 5,833,956). Xu et al. disclose dentifrice gel or paste compositions comprising about 40% to 70% by weight baking soda (sodium bicarbonate), natural or herbal ingredients, flavoring oils, xanthan gum, at least of betaine surfactant and a humectant (Abstract). The compositions also comprise water (Examples). Dentifrices have long been known and used to clean teeth and to combat plaque (paragraph 0003). Betaines include cocoamidopropyl betaine and cocoamidosulfobetaine and comprise 0.5 to 5% by weight of the composition (paragraph 0014). Sodium lauryl sulfate maybe used and comprises less than 2%. Natural or herbal ingredients include aloe (an anti-inflammatory agent, meeting instant claim 8). Sweeteners include stevioside (stevia) and comprise less than about 1% of the dentifrice formulations (paragraph 0033). A compositions comprises 67.262% baking soda, 0.85% xanthan gum, 4% cocoamidopropyl betaine (30%), glycerin, peppermint oil, sage oil and water (TABLE 1, Formula A). Xu et al. differ from the instant claims insofar as they do not disclose that sodium lauryl sulfate is used in combination with a betaine surfactant. Gorlin et al. disclose oral care compositions comprising a surfactant system comprising a mixture of two or more surfactants. One embodiment comprises a mixture of sodium lauryl sulfate and a betaine. The amount of sodium lauryl sulfate is used in an amount higher than the betaine. It was seen that when an additional surfactant was used, the compositions exhibited higher foam levels than when SLS alone was the sole surfactant (col. 6). The same amount of total surfactant was used in all the examples of TABLE I. When a combination of SLS and CAPB was used in a ratio of 4:1, the foaming went up almost 2 fold. Therefore, it would have been obvious to one of ordinary skill in the art prior to filing the instant application to have used a combination of sodium lauryl sulfate and cocoamidopropyl betaine in a ratio of 1:4 because this combination will improve foaming without the need for additional total surfactant. It would have been obvious to one of ordinary skill in the art prior to filing the instant application to have used 65% to 70% sodium bicarbonate in the composition of Gorlin et al. because it is disclosed by Gorlin et al. as a suitable polishing agent and 65% to 70% is suitable for use in oral care compositions, as disclosed by Xu et al. Conclusion Claims 1-4 and 6-8 are rejected. No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached on 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Mar 19, 2020
Application Filed
Mar 19, 2020
Response after Non-Final Action
Jun 05, 2021
Non-Final Rejection — §103, §112
Sep 10, 2021
Response Filed
Dec 04, 2021
Final Rejection — §103, §112
Mar 16, 2022
Applicant Interview (Telephonic)
Mar 18, 2022
Examiner Interview Summary
Apr 11, 2022
Response after Non-Final Action
May 09, 2022
Request for Continued Examination
May 10, 2022
Response after Non-Final Action
Jun 18, 2022
Non-Final Rejection — §103, §112
Oct 24, 2022
Response Filed
Dec 17, 2022
Final Rejection — §103, §112
Feb 22, 2023
Response after Non-Final Action
Mar 15, 2023
Request for Continued Examination
Mar 16, 2023
Response after Non-Final Action
Mar 24, 2023
Non-Final Rejection — §103, §112
Jun 29, 2023
Response Filed
Oct 15, 2023
Final Rejection — §103, §112
Jan 18, 2024
Request for Continued Examination
Jan 19, 2024
Response after Non-Final Action
Jan 27, 2024
Non-Final Rejection — §103, §112
Apr 30, 2024
Response after Non-Final Action
Apr 30, 2024
Notice of Allowance
May 08, 2024
Response after Non-Final Action
Jul 29, 2024
Response after Non-Final Action
Jul 29, 2024
Response after Non-Final Action
Aug 09, 2024
Response after Non-Final Action
Aug 14, 2024
Response after Non-Final Action
Aug 16, 2024
Response after Non-Final Action
Aug 16, 2024
Response after Non-Final Action
Dec 02, 2024
Response after Non-Final Action
Feb 05, 2025
Response after Non-Final Action
Feb 05, 2025
Response after Non-Final Action
Feb 06, 2025
Response after Non-Final Action
Feb 06, 2025
Response after Non-Final Action
Nov 18, 2025
Response after Non-Final Action
Jan 16, 2026
Request for Continued Examination
Jan 20, 2026
Response after Non-Final Action
Feb 07, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594229
Personal Care Compositions and Methods for the Same
2y 5m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
2y 5m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 5m to grant Granted Feb 24, 2026
Patent 12551417
STABILIZED STANNOUS COMPOSITIONS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

8-9
Expected OA Rounds
48%
Grant Probability
85%
With Interview (+36.4%)
4y 4m
Median Time to Grant
High
PTA Risk
Based on 750 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month